The present study provides insight into the mechanism by which recombinant IL-37 exerts its anti-inflammatory action on human AVICs and may facilitate the development of therapeutic approaches for prevention of CAVD progression. The gene discussed is IL37; the disease is congenital bilateral aplasia of vas deferens from CFTR mutation.